Famar L'Aigle

Delpharm L'Aigle, formerly known as Famar L'Aigle, is a specialized pharmaceutical manufacturing facility located in L'Aigle, France. The site was acquired by the Delpharm Group in November 2019 following the restructuring of the Famar Group. It serves as a Contract Development and Manufacturing Organization (CDMO) focused on the production of solid oral dosage forms, including tablets, hard capsules, and sugar-coated tablets. With a workforce of approximately 250 employees, the facility provides large-scale commercial manufacturing and packaging services for global pharmaceutical partners. The plant is GMP-certified and maintains a strong reputation for technical expertise in complex coating processes.